Inovio Shares Sink After Pricing $25M Public Offering

Dow Jones

23小時前

By Connor Hart

Shares of Inovio Pharmaceuticals fell after the company priced a $25 million public offering.

The stock slid 6.5% to $2.01 on Tuesday. Despite losing more than 60% of their value over the past year, shares have gained roughly 35% in the past three months.

Ahead of the opening bell, the drugmaker said it plans to sell about 13.2 million shares of common stock at $1.90 apiece. Inovio will also grant underwriters a 30-day option to purchase up to nearly 2 million shares at the offering price, minus underwriting fees.

Piper Sandler & Co. is acting as sole manager for the offering, and all shares are being sold by Inovio. The offering is expected to close on or about Nov. 12.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

November 11, 2025 11:21 ET (16:21 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582393460"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582393460\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582393460?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 00:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582393460","market":"nz","top_or_hot":-1,"title":"Inovio Shares Sink After Pricing $25M Public Offering","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Inovio Pharmaceuticals fell after the company priced a $25 million public offering. \n</p>\n<p>\n  The stock slid 6.5% to $2.01 on Tuesday. Despite losing more than 60% of their value over the past year, shares have gained roughly 35% in the past three months. \n</p>\n<p>\n  Ahead of the opening bell, the drugmaker said it plans to sell about 13.2 million shares of common stock at $1.90 apiece. Inovio will also grant underwriters a 30-day option to purchase up to nearly 2 million shares at the offering price, minus underwriting fees. \n</p>\n<p>\n  Piper Sandler &amp; Co. is acting as sole manager for the offering, and all shares are being sold by Inovio. The offering is expected to close on or about Nov. 12. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 11, 2025 11:21 ET (16:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inovio Shares Sink After Pricing $25M Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInovio Shares Sink After Pricing $25M Public Offering\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-11-12 00:21</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Inovio Pharmaceuticals fell after the company priced a $25 million public offering. \n</p>\n<p>\n  The stock slid 6.5% to $2.01 on Tuesday. Despite losing more than 60% of their value over the past year, shares have gained roughly 35% in the past three months. \n</p>\n<p>\n  Ahead of the opening bell, the drugmaker said it plans to sell about 13.2 million shares of common stock at $1.90 apiece. Inovio will also grant underwriters a 30-day option to purchase up to nearly 2 million shares at the offering price, minus underwriting fees. \n</p>\n<p>\n  Piper Sandler &amp; Co. is acting as sole manager for the offering, and all shares are being sold by Inovio. The offering is expected to close on or about Nov. 12. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 11, 2025 11:21 ET (16:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4583","symbol_name":"猴痘概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2582393460","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582393460","pubTimestamp":1762878060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Inovio Pharmaceuticals fell after the company priced a $25 million public offering.The stock slid 6.5% to $2.01 on Tuesday. Despite losing more than 60% of their value over the past year, shares have gained roughly 35% in the past three months.Ahead of the opening bell, the drugmaker said it plans to sell about 13.2 million shares of common stock at $1.90 apiece. Inovio will also grant underwriters a 30-day option to purchase up to nearly 2 million shares at the offering price, minus underwriting fees.Piper Sandler & Co. is acting as sole manager for the offering, and all shares are being sold by Inovio. The offering is expected to close on or about Nov. 12.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4583":"猴痘概念","BK4139":"生物科技","INO":"伊诺维奥制药","BK4568":"美国抗疫概念"},"translate_title":"Inovio公开发行2500万美元后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INO":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Inovio Pharmaceuticals fell after the company priced a $25 million public offering. \n\n\n  The stock slid 6.5% to $2.01 on Tuesday. Despite losing more than 60% of their value over the past year, shares have gained roughly 35% in the past three months. \n\n\n  Ahead of the opening bell, the drugmaker said it plans to sell about 13.2 million shares of common stock at $1.90 apiece. Inovio will also grant underwriters a 30-day option to purchase up to nearly 2 million shares at the offering price, minus underwriting fees. \n\n\n  Piper Sandler & Co. is acting as sole manager for the offering, and all shares are being sold by Inovio. The offering is expected to close on or about Nov. 12. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2025 11:21 ET (16:21 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}